CVS Caremark’s decision to place Wegovy over Zepbound could give Novo an edge as the companies fight to convince insurance companies to pay for their treatments, which cost more than $1,000 a ...

For CVS Health CVS, the key to building customer trust is to enhance access to life-changing medications and also make them affordable. Beginning July 1, the company’s Pharmacy Benefit Manager (“PBM”) ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's Wegovy for weight loss — a major blow to the Indianapolis pharmaceutical ...

Summary. Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025.

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

I can tell you that my team and I are in direct discussions with CVS Caremark to advocate for Zepbound’s inclusion and to push for continued access for patients already on treatment. ...

Caremark will also drop the weight loss drug Zepbound from its standard formularies on that date, in a blow to its manufacturer, Eli Lilly, a CVS spokesperson told CNBC.

CVS’s drug-benefits unit, known as Caremark, earlier this month negotiated a deal to make Novo’s Wegovy more widely available to its customers — knocking Eli Lilly & Co.’s Zepbound off its ...

CVS Caremark, the largest pharmacy ... with Zepbound leading to greater weight loss than Wegovy and with Lilly having what look to be more promising injectable and oral candidates in its pipeline.

Caremark will also drop the weight loss drug Zepbound from its standard formularies on that date, in a blow to its manufacturer, Eli Lilly, a CVS spokesperson told CNBC.